FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995994179> ?p ?o ?g. }

• W1995994179 endingPage "1959" @default.
• W1995994179 startingPage "1947" @default.
• W1995994179 abstract "Background: Metastatic bone disease is a serious clinical problem in patients with advanced cancer. Bisphosphonates inhibit the activity of osteoclasts and are the treatment of choice for bone metastases. Objective: This article reviews the efficacy and safety data from Phase III trials of ibandronate in metastatic bone disease. Methods: Phase III data (available as of June 2004) for ibandronate were reviewed. Literature searches using the MEDLINE database and abstracts from scientific meetings were used to obtain data from Phase III trials of ibandronate. Results: Compared with placebo, patients with bone metastases from breast cancer receiving IV ibandronate (6 mg infused over 1–2 hours every 3–4 weeks) or oral ibandronate (50 mg/d for up to 96 weeks) had a statistically significant reduction in skeletal complications, as measured by the Skeletal Morbidity Period Rate (P = 0.004 vs placebo). Multivariate Poisson regression analysis of the data showed that the risk of a new bone event was reduced by 40% with IV ibandronate 6 mg and by 38% with oral ibandronate 50 mg, compared with placebo (P ≤ 0.003). Both formulations also reduced bone pain below baseline levels over 2 years (P ≤ 0.001 vs placebo). IV and oral ibandronate were well tolerated, with adverse-event profiles comparable to placebo and no significant renal toxicity. Conclusions: IV and oral ibandronate provide meaningful clinical benefits in patients with bone metastases from breast cancer. Both formulations reduce the risk of skeletal events and provide sustained relief from metastatic bone pain. With its favorable efficacy and safety profile, and the added convenience of the oral formulation, ibandronate provides improved treatment options for managing metastatic bone disease." @default.
• W1995994179 created "2016-06-24" @default.
• W1995994179 creator A5025636086 @default.
• W1995994179 creator A5057008789 @default.
• W1995994179 creator A5079515382 @default.
• W1995994179 date "2004-12-01" @default.
• W1995994179 modified "2023-09-25" @default.
• W1995994179 title "Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials" @default.
• W1995994179 cites W1537575553 @default.
• W1995994179 cites W1873492158 @default.
• W1995994179 cites W1925515170 @default.
• W1995994179 cites W1937662086 @default.
• W1995994179 cites W1954585625 @default.
• W1995994179 cites W1967875617 @default.
• W1995994179 cites W1969128375 @default.
• W1995994179 cites W1969222077 @default.
• W1995994179 cites W1975154215 @default.
• W1995994179 cites W1976400797 @default.
• W1995994179 cites W1982915376 @default.
• W1995994179 cites W1987376337 @default.
• W1995994179 cites W1991901472 @default.
• W1995994179 cites W1995580211 @default.
• W1995994179 cites W2004931703 @default.
• W1995994179 cites W2005011084 @default.
• W1995994179 cites W2007001439 @default.
• W1995994179 cites W2010486222 @default.
• W1995994179 cites W2011422517 @default.
• W1995994179 cites W2035190861 @default.
• W1995994179 cites W2048162835 @default.
• W1995994179 cites W2051112719 @default.
• W1995994179 cites W2051743148 @default.
• W1995994179 cites W2053802095 @default.
• W1995994179 cites W2062417991 @default.
• W1995994179 cites W2067254457 @default.
• W1995994179 cites W2068136195 @default.
• W1995994179 cites W2087929119 @default.
• W1995994179 cites W2088500774 @default.
• W1995994179 cites W2091262790 @default.
• W1995994179 cites W2099268304 @default.
• W1995994179 cites W2101270823 @default.
• W1995994179 cites W2115871403 @default.
• W1995994179 cites W2117800069 @default.
• W1995994179 cites W2119161416 @default.
• W1995994179 cites W2121051980 @default.
• W1995994179 cites W2131217979 @default.
• W1995994179 cites W2149876087 @default.
• W1995994179 cites W2159100092 @default.
• W1995994179 cites W2161962336 @default.
• W1995994179 cites W2166444926 @default.
• W1995994179 cites W2181556721 @default.
• W1995994179 cites W2401709656 @default.
• W1995994179 cites W2412929961 @default.
• W1995994179 cites W2415312306 @default.
• W1995994179 cites W2607028219 @default.
• W1995994179 cites W4295846566 @default.
• W1995994179 cites W65788409 @default.
• W1995994179 cites W2041009051 @default.
• W1995994179 doi "https://doi.org/10.1016/j.clinthera.2004.12.010" @default.
• W1995994179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15823760" @default.
• W1995994179 hasPublicationYear "2004" @default.
• W1995994179 type Work @default.
• W1995994179 sameAs 1995994179 @default.
• W1995994179 citedByCount "23" @default.
• W1995994179 countsByYear W19959941792012 @default.
• W1995994179 countsByYear W19959941792013 @default.
• W1995994179 countsByYear W19959941792015 @default.
• W1995994179 crossrefType "journal-article" @default.
• W1995994179 hasAuthorship W1995994179A5025636086 @default.
• W1995994179 hasAuthorship W1995994179A5057008789 @default.
• W1995994179 hasAuthorship W1995994179A5079515382 @default.
• W1995994179 hasConcept C121608353 @default.
• W1995994179 hasConcept C126322002 @default.
• W1995994179 hasConcept C126894567 @default.
• W1995994179 hasConcept C141071460 @default.
• W1995994179 hasConcept C142724271 @default.
• W1995994179 hasConcept C143998085 @default.
• W1995994179 hasConcept C197934379 @default.
• W1995994179 hasConcept C204787440 @default.
• W1995994179 hasConcept C27081682 @default.
• W1995994179 hasConcept C2775930923 @default.
• W1995994179 hasConcept C2776139714 @default.
• W1995994179 hasConcept C2776169692 @default.
• W1995994179 hasConcept C2776541429 @default.
• W1995994179 hasConcept C2777783956 @default.
• W1995994179 hasConcept C530470458 @default.
• W1995994179 hasConcept C535046627 @default.
• W1995994179 hasConcept C71924100 @default.
• W1995994179 hasConceptScore W1995994179C121608353 @default.
• W1995994179 hasConceptScore W1995994179C126322002 @default.
• W1995994179 hasConceptScore W1995994179C126894567 @default.
• W1995994179 hasConceptScore W1995994179C141071460 @default.
• W1995994179 hasConceptScore W1995994179C142724271 @default.
• W1995994179 hasConceptScore W1995994179C143998085 @default.
• W1995994179 hasConceptScore W1995994179C197934379 @default.
• W1995994179 hasConceptScore W1995994179C204787440 @default.
• W1995994179 hasConceptScore W1995994179C27081682 @default.
• W1995994179 hasConceptScore W1995994179C2775930923 @default.
• W1995994179 hasConceptScore W1995994179C2776139714 @default.

• next